Arbutus Biopharma/$ABUS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Arbutus Biopharma
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
- Ticker
- $ABUS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 19
- Headquarters
- Warminster, United States
- Website
- www.arbutusbio.com
ABUS Metrics
BasicAdvanced
$847M
5.42
$0.79
0.60
-
Price and volume
Market cap
$847M
Beta
0.6
52-week high
$5.45
52-week low
$3.50
Average daily volume
6.2M
Financial strength
Current ratio
81.416
Quick ratio
81.084
Long term debt to equity
0.012
Total debt to equity
0.014
Interest coverage (TTM)
1,939.86%
Profitability
EBITDA (TTM)
147.473
Gross margin (TTM)
90.20%
Net profit margin (TTM)
84.23%
Operating margin (TTM)
81.13%
Revenue per employee (TTM)
$9,560,000
Management effectiveness
Return on assets (TTM)
48.84%
Return on equity (TTM)
89.58%
Valuation
Price to earnings (TTM)
5.421
Price to revenue (TTM)
4.566
Price to book
3.27
Price to tangible book (TTM)
3.27
Price to free cash flow (TTM)
-33.692
Free cash flow yield (TTM)
-2.97%
Free cash flow per share (TTM)
-0.127
Growth
Revenue change (TTM)
1,078.78%
Earnings per share change (TTM)
-374.78%
3-year revenue growth (CAGR)
97.65%
10-year revenue growth (CAGR)
26.25%
3-year earnings per share growth (CAGR)
19.74%
10-year earnings per share growth (CAGR)
-14.02%
Bulls say / Bears say
Imdusiran has shown a potentially meaningful functional-cure signal: eight patients achieved functional cure in Phase 2a combination trials, with six maintaining it for more than two years; two further patients achieved cure during long-term follow-up. If larger trials confirm the durability, the drug could address a major unmet need. (Arbutus Biopharma Corporation)
The FDA granted imdusiran Fast Track status and aligned with Arbutus on the proposed Phase 2b trial design and safety parameters. This reduces some regulatory uncertainty as the company finalises the study protocol. (Arbutus Biopharma Corporation)
Arbutus received about $178 million from the non-contingent Moderna settlement, then completed a $230 million tender offer that bought back 46 million shares, or about 23% of its outstanding shares. The cash receipt and smaller share count strengthen the financial and per-share case, although the repurchase used substantial capital. (GlobeNewswire, SEC)
The reported functional cures came from combination regimens, not imdusiran alone, and involved a small number of patients. Phase 2b must show whether imdusiran adds meaningful benefit and whether the results hold in a broader group. (Arbutus Biopharma Corporation)
Arbutus remains clinical-stage, and second-quarter revenue was only $1.0 million versus $10.7 million a year earlier; the earlier figure included $9.6 million of deferred Qilu revenue recognised once. Near-term value therefore relies on clinical progress and external IP proceeds rather than a recurring product-sales base. (Arbutus Biopharma Corporation)
The potential additional $1.3 billion Moderna payment is not assured: it depends on the outcome of a legal appeal, and the US government has filed in support of Moderna’s position. That makes a large part of the potential LNP value legally contingent. (JDSupra)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
ABUS Financial Performance
Revenues and expenses
ABUS Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing ABUS
Fund name | Fund size | $ABUS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.06% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.06% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.03% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.